Hurdles to clinical translation of human induced pluripotent stem cells
Evgenios Neofytou, … , Larry A. Couture, Joseph C. Wu
Evgenios Neofytou, … , Larry A. Couture, Joseph C. Wu
Published July 1, 2015
Citation Information: J Clin Invest. 2015;125(7):2551-2557. https://doi.org/10.1172/JCI80575.
View: Text | PDF
Review

Hurdles to clinical translation of human induced pluripotent stem cells

Abstract

Human pluripotent stem cells are known to have the capacity to renew indefinitely, being intrinsically able to differentiate into many different cell types. These characteristics have generated tremendous enthusiasm about the potential applications of these cells in regenerative medicine. However, major challenges remain with the development and testing of novel experimental stem cell therapeutics in the field. In this Review, we focus on the nature of the preclinical challenges and discuss potential solutions that could help overcome them. Furthermore, we discuss the use of allogeneic versus autologous stem cell products, including a review of their respective advantages and disadvantages, major clinical requirements, quality standards, time lines, and costs of clinical grade development.

Authors

Evgenios Neofytou, Connor Galen O’Brien, Larry A. Couture, Joseph C. Wu

×

Figure 1

Flow chart of pluripotent stem cell banking.

Options: View larger image (or click on image) Download as PowerPoint
Flow chart of pluripotent stem cell banking. Human PSCs are ideal candid...
Human PSCs are ideal candidates for developing cell therapies from either a tissue biopsy or blood collection (i). Allogeneic and autologous stem cell banking requires establishment and expansion of the starting pluripotent material (ii). Human ESCs and iPSCs are capable of differentiating into any adult cell type (iii). Therapeutically relevant cell products must undergo preclinical studies required by the FDA prior to an IND application (iv). TSE, transmissible spongiform encephalopathy. Cells must undergo processing prior to secure cryostorage (v). The cryopreserved products may either be used immediately or be held for future use as allografts in order to regenerate damaged organs (vi).